Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Effect of DPP Inhibitors on the
2021-03-02

Effect of DPP-4 Inhibitors on the Clinical Course of Heart Failure Four large-scale cardiovascular outcomes trials with DPP-4 inhibitors have been completed, and their findings have been published (Table 1) 31, 32, 33, 34. In 2 studies (with saxagliptin and alogliptin), DPP-4 inhibition was accom
-
In our current work we have undertaken liquid phase
2021-03-02

In our current work, we have undertaken liquid phase combinatorial synthesis methods for the synthesis of 1,2,5-trisubstituted benzimidazole derivatives as hDHODH inhibitors. Synthesised ldk378 were also screened by molecular docking studies over the reported hDHODH structure. The synthesised molecu
-
Some limitations to our study should be noted
2021-03-02

Some limitations to our study should be noted. First, the sample size of our study was limited. As DDR2 mutations are rare in lung SCC, it is possible that the power of our study was insufficient to detect potential associated factors. Second, a significant proportion of the 271 sequenced patients h
-
Several reasons may explain that other studies using
2021-03-02

Several reasons may explain that other studies using PDE-5-Is yielded negative or contradictory results [30], [31], [32]. Lee [30] applied 50mg sildenafil to seven patients with liver cirrhosis. NO and cGMP in the hepatic Ch 55 synthesis significantly increased, hepatic and pulmonary resistance de
-
Grapiprant is a selective antagonist
2021-03-02

Grapiprant () is a selective antagonist for prostaglandin E (PGE) receptor subtype 4 (EP4) identified as a clinical candidate for the treatment of inflammatory pain associated with osteoarthritis (OA). It is currently under development for use in humans and dogs. The projected dosing regimen of grap
-
Furan analogs and N methylpyrrole analogs had
2021-03-02

Furan analogs and N-methylpyrrole analogs had completely different SARs. For example, replacement of the furan-2-sulfonyl moiety of 6 with the furan-3-sulfonyl moiety resulted in 8 with a decreased EP1 SB 265610 affinity and an increased antagonist activity, while the corresponding chemical modific
-
A wealth of studies support the
2021-03-02

A wealth of studies support the key role of high NO in promoting higher blood flow and thus greater O2 delivery to working tissues in healthy Tibetans and thus partly compensate hypoxia induced low arterial O2 content [7,9,27]. We observed high eNOS mRNA, protein and enzyme activity in Ladakhi women
-
Upon Edn ligand binding endothelin receptors can induce a
2021-03-02

Upon Edn ligand binding, endothelin receptors can induce a variety of intracellular signaling cascades leading to diverse cellular responses such as contraction in the case of smooth muscle cells, or cell growth and mitogenesis. Ednrs are expressed in a variety of cell types and tissues, for example
-
In the course of this study K
2021-03-01

In the course of this study, K+PFOS did not appear to have any effect on the thyroid parameters evaluated (H&E histology, follicular epithelial cell proliferation, and follicular epithelial apoptosis). This is an interesting observation considering the fact that treatment with K+PFOS resulted in act
-
BET bromodomain inhibitor australia br Materials and methods
2021-03-01

Materials and methods Results Discussion Oxidative stress is a disturbance in the balance of pro- and antioxidant species, resulting in oxidative damage to membrane proteins, lipids, and DNA. Oxidative stress is a predisposing factor for the progression of metabolic diseases and liver injur
-
CYP A and CYP D
2021-03-01

CYP3A4/5 and CYP2D6 are among the main drug-metabolizing enzymes in humans that are responsible for the metabolism of more than 50% of marketed drugs [19], [21]. Drugs metabolized by CYPs are prone to drug–drug interactions, thereby modifying their response [18], [32]. Metabolic inhibition is also i
-
The lack of robust immunocompetent animal models permissive
2021-03-01

The lack of robust immunocompetent animal models permissive for HCV makes it hard to assess if the quantity and quality of vaccine-induced immunity is sufficient to confer protection. Thus, it is difficult to predict to what extent antibody responses induced by current vaccination approaches, includ
-
leukotriene receptor antagonist Acanthopanax senticosus Rupr
2021-03-01

Acanthopanax senticosus (Rupr. & Maxim.) Harms, a nontoxic herb belongs to the family of Araliaceae, which found in Northeast Asia. A. senticosus traditionally used as a tonic to treat rheumatism, diabetes, and hepatitis [7]. Previous phytochemical and biological investigations found its roots and s
-
Mizoribine At ngL DEX did not
2021-03-01

At 3000ngL−1, DEX did not affect our investigated parameters, suggesting that DEX is regulated by CYP450 in a biphasic way, a response to xenobiotics that is not uncommon (Heinrichs et al., 1994). These data might also suggest that fish adapted to DEX exposure. It was previously shown that, dependin
-
We next considered the mechanism of the hepatospecific
2021-03-01

We next considered the mechanism of the hepatospecific decrease in CYP3A exerted by EGCG. We examined the possibility that orally administered EGCG was absorbed from the intestine and directly decreased the CYP3A expression level in the liver. Although the Ryuvidine rate of orally administered EGCG
16289 records 727/1086 page Previous Next First page 上5页 726727728729730 下5页 Last page